Treatment of Acute Myeloid Leukemia in BCR-ABL1-Positive Disease

Clinical Scenario

This protocol addresses acute myeloid leukaemia (AML) in patients whose disease is BCR-ABL1-positive — a molecularly defined subgroup with limited published evidence. A specific, evidence-guided approach is required for this population.

Specific Population

BCR-ABL1-positive AML is a distinct molecular subset. Data on treatment are limited, making structured, evidence-based regimen guidance particularly important when managing these patients.

Clinical goal: Achievement of remission

Treatment Approach (partial overview)

For TKI-naive patients, management centres on a tyrosine-kinase inhibitor (TKI)-based strategy. Achieving remission is the central objective. The complete regimen — including sequencing, combination options, and post-remission management — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

There are limited data on the treatment of BCR-ABL1-positive AML.
Tyrosine-kinase inhibitor (TKI)-naive patients should be treated with a second-line TKI with or without induction ChT [II, A].
BCR-ABL-positive patients should undergo alloHCT as soon as they achieve remission.
In BCR-ABL-positive patients, TKI maintenance after alloHCT is recommended [V, B].

View source ↗